Patent ID: 11884978
Assignee: IMMUNEXPRESS PTY LTD
Field: Measurement (Instruments)
Classification: CPC C  G | IPC C  G

Claim 1:
2. The method of claim 1, wherein
the derived biomarker value of (2) is a first derived biomarker value, the method further comprising:
(5) in the blood sample taken from the subject, measuring an expression level for an expression product of OASL and an expression level for an expression product of CD97;
(6) determining a second derived biomarker value for the blood sample, the second derived biomarker value being a ratio of the expression level of the expression product of OASL to the expression level of the expression product of CD97;
(7) combining the first derived biomarker value and the second derived biomarker value into a combined biomarker value;
(8) determining whether the combined biomarker value for the blood sample is greater than a reference combined biomarker value determined from expression levels for a polynucleotide expression product of ISG15, a polynucleotide expression product of IL16, an expression product of OASL, and an expression product of CD97 in samples from non-VaSIRS control subjects; and
(4) if the combined biomarker value for the blood sample is greater than the reference combined biomarker value, administering to the subject an effective amount of a VaSIRS therapeutic agent.